5-Panel vs. 10-Panel vs. Expanded Drug Tests for Research Studies
Published October 2026 by the DrugScreens.com Editorial Team. 6 minute read.
Quick answer: which panel size fits a research study?
A 5-panel drug test screens for five core drug classes and suits eligibility screens and studies with a narrow substance focus. A 10-panel drug test adds prescription classes such as benzodiazepines, methadone, oxycodone and buprenorphine. Expanded panels of 12 to 22 analytes add targets such as fentanyl, EtG, tramadol, K2 and kratom. The right panel is the one the IRB-approved protocol names. A bigger panel is not automatically a better panel, and CLIA-waived status often changes as panels expand.
Research coordinators ask the same question at the start of almost every study: how many panels does the protocol actually need? This post compares the 5-panel drug test for research, the 10-panel drug test for research, and expanded panel drug testing side by side.
This comparison is a companion to the DrugScreens.com guide to drug testing and drug screening for university research, which covers specimen types, documentation and procurement in more depth.
What a "panel" means on a research drug test
A panel is one analyte. Each test strip on a cup or dip card is an immunoassay that reacts to one drug or drug class at a fixed cutoff level. A 5-panel device carries five strips. A 16-panel device carries sixteen.
Every rapid screen produces a preliminary result. A non-negative result is not a confirmed positive. The protocol should state whether laboratory confirmation by GC-MS or LC-MS/MS follows.
Panel size applies to both formats. Multi-panel urine drug test cups combine collection and screening in one device. Urine drug test dip cards are dipped into a specimen collected separately.
5-panel drug test for research: the baseline
The standard 5-panel configuration screens for amphetamine (AMP), cocaine (COC), methamphetamine (MET), opiates (OPI) and marijuana (THC).
A 5-panel test fits enrollment and eligibility screening, baseline assessment, and studies where the research question involves only traditional drug classes. A 5-panel test also keeps cost per screen low across large cohorts and repeated visits.
The limit of a 5-panel test is coverage. The OPI strip targets morphine-type opiates. The OPI strip does not reliably detect oxycodone, methadone, buprenorphine or fentanyl. A study that depends on any of those substances needs more than five panels.
10-panel drug test for research: adding prescription classes
A common 10-panel configuration keeps the core five and adds benzodiazepines (BZO), barbiturates (BAR), methadone (MTD), oxycodone (OXY) and buprenorphine (BUP). Exact analytes vary by product, so the product listing should be checked against the protocol.
A 10-panel test suits addiction medicine research, medication-assisted treatment (MAT) studies and behavioral health studies that track polysubstance use. Dedicated MTD and BUP strips let a study observe treatment medications separately from other opioids.
A standard 10-panel test still has no fentanyl strip. Research teams studying the current illicit opioid supply should not assume that a 10-panel test covers fentanyl.
Expanded panel drug testing: 12 panels and beyond
Expanded panels run from 12 to 22 analytes. Expanded configurations add targets that standard panels miss, including fentanyl (FTY), ethyl glucuronide (EtG, an alcohol biomarker), tramadol (TRA), synthetic cannabinoids (K2), kratom and ketamine.
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, supports research on drug use and addiction and publishes research topic pages on fentanyl, xylazine, kratom and other emerging substances. Research teams can use NIDA resources to judge which analytes are relevant to a study population before choosing a panel.
Expanded panels fit harm reduction research, studies of emerging drug trends and protocols that need broad polysubstance profiling. Extra analytes that do not serve the research question add cost and add non-negative results that the protocol must then handle.
CLIA-waived status changes as panels expand
Classification belongs to the specific test system, not to a brand or a panel count. Research teams should confirm the classification of the exact product before ordering.
On DrugScreens.com, most CLIA-waived urine drug test cups and dip cards fall in the standard range, including 5-panel, 10-panel, 12-panel and 13-panel configurations from SAFElife and Healgen.
Many expanded configurations are different. Cups that add EtG, tramadol, K2 or kratom at 14 panels and above are commonly labeled Forensic Use Only (FUO). A Forensic Use Only device is not a CLIA-waived device.
Oral fluid is a separate category. Saliva drug test kits are classified as Employment and Insurance Use or Forensic Use Only. Saliva kits are not CLIA waived and should never be described as CLIA-waived drug test kits in a protocol or purchase request.
Protocol note: If the IRB-approved protocol or the institution requires CLIA-waived devices, an expanded Forensic Use Only cup or a saliva kit does not meet that requirement. A CLIA-waived multi-panel cup paired with a CLIA-waived single-panel dip card may cover the same analytes.
How to match a panel to the protocol
- List the analytes the research question requires. Start from the study aims, not from a catalog.
- Check the study population. Regional drug supply and expected substance use decide whether fentanyl, EtG or kratom belong on the panel.
- Confirm the required classification. Ask the IRB and compliance office whether the protocol requires CLIA-waived devices.
- Choose the smallest panel that covers every required analyte. Add a single-panel dip card when one extra analyte is needed.
- Lock the configuration for the full study. Changing panels or cutoffs mid-study introduces a confounding variable.
Buying drug test kits in bulk for a study
Most urine drug test kits for clinical research ship in boxes of 25. A study with 150 participants and 4 screening visits needs 600 screens before contingency. A buffer of 15 to 20 percent covers invalid specimens, added visits and staff training.
Research teams that buy drug test kits in bulk in a single order reduce the risk of a mid-study product change and can match expiration dates to the study timeline. DrugScreens.com supplies bulk drug testing supplies with volume pricing, purchase order support and lot-specific documentation.
Drug testing supplies for research studies should be ordered by case quantity, with the same product and configuration from enrollment through the final visit.
Frequently asked questions
Is a 10-panel drug test better than a 5-panel drug test for research?
No. A 10-panel test screens for more drug classes, but the better test is the one that matches the analytes named in the IRB-approved protocol.
Does a 5-panel or 10-panel drug test detect fentanyl?
Standard 5-panel and 10-panel tests do not include a fentanyl strip. Fentanyl screening requires a dedicated FTY analyte on an expanded panel or a single-panel fentanyl dip card.
Are expanded panel drug tests CLIA waived?
Some are and many are not. Classification depends on the exact product. Many expanded cups with EtG, tramadol, K2 or kratom are Forensic Use Only.
Are saliva drug tests CLIA waived for research use?
No. Saliva drug test kits are classified as Employment and Insurance Use or Forensic Use Only. Most urine cups and dip cards are CLIA waived.
Planning panel selection for a research study?
DrugScreens.com can help research teams compare configurations and estimate study quantities. Call 800-652-3502 or email sales@drugscreens.com.
Shop urine drug test cupsRequest bulk pricing
This content is provided for general informational purposes only and does not constitute legal advice, regulatory guidance, or IRB or compliance consultation. DrugScreens.com supplies drug screening devices and does not provide laboratory services, medical diagnostics, IRB guidance, or drug testing program administration. Research teams should consult with their IRB, institutional compliance office, principal investigator, and qualified legal and regulatory counsel before implementing any drug screening protocol.
